Value of lumbar puncture in the diagnosis of infantile epilepsy and folinic acid-responsive seizures

Journal of Child Neurology

Volumn 17, Issue SUPPL. 3, 2002, Pages

  Hyland, Keith ^a   Arnold, Lauren A ^a  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; CATECHOLAMINE; CREATINE; FOLINIC ACID; SERINE;

BIOACCUMULATION; BIOSYNTHESIS; BLOOD ANALYSIS; CENTRAL NERVOUS SYSTEM; CEREBROSPINAL FLUID ANALYSIS; CHILD; CHILDHOOD DISEASE; DIAGNOSTIC PROCEDURE; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; ENERGY METABOLISM; GLUCOSE TRANSPORT; HUMAN; INBORN ERROR OF METABOLISM; INFANT; INFANTILE EPILEPSY; LUMBAR PUNCTURE; METABOLITE; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; ONSET AGE; PRIORITY JOURNAL; REVIEW; SEIZURE; SEROTONINERGIC SYSTEM; URINALYSIS;

ANTICONVULSANTS; BIOGENIC AMINES; BIOLOGICAL MARKERS; HUMANS; INFANT; LABORATORY TECHNIQUES AND PROCEDURES; LEUCOVORIN; METABOLISM, INBORN ERRORS; SPASMS, INFANTILE; SPINAL PUNCTURE; TREATMENT OUTCOME;

EID: 0037000428     PISSN: 08830738     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (61)

1. Brown GK, Haan EA, Kirby DM, et al: "Cerebral" lactic acidosis: Defects in pyruvate metabolism with profound brain damage and minimal systemic acidosis. Eur J Pediatr 1988;147:10-14.
2. DeVivo, DC, Trifiletti RR, Jacobson RL, et al: Defective glucose transport across the blood-brain barrier as a cause of persistent hypoglycorrhachia, seizures, and developmental delay. N Engl J Med 1991;325:703-709.
3. Tada K, Hayasaka K: Non-ketotic hyperglycinaemia: Clinical and biochemical aspects. Eur J Pediatr 1987;146:221-227.
4. de Koning TJ, Poll-The BT, Jaeken J: Continuing education in neurometabolic disorders-Serine deficiency disorders. Neuropediatrics 1999;30:1-4.
5. Jaeken J, Detheux M, Van Maldergem L, et al: 3-Phosphoglycerate dehydrogenase deficiency and 3-phosphoserine phosphatase deficiency: Inborn errors of serine biosynthesis. J Inherit Metab Dis 1996;19:223-226.
6. Grove J, Schechter PJ, Tell G, et al: Artifactual increases in the concentration of free GABA in samples of human cerebrospinal fluid are due to degradation of homocarnosine. J Neurochem 1982;39:1061-1065.
7. Struys EA, Guerand WS, ten Brink HJ, Jakobs C: Combined method for the determination of gamma-aminobutyric and beta-alanine in cerebrospinal fluid by stable isotope dilution mass spectrometry. J Chromatogr B Biomed Sci Appl 1999;732:245-249.
8. Giroux JD, Moisan-Cann C, Caroff J, et al: Gamma-aminobutyric acid concentrations in the cerebrospinal fluid of newborn infants determined by high performance liquid chromatography. Acta Paediatr 1996;85:595-597.
9. Naini AB, Vontzalidou E, Cote LJ: Isocratic HPLC assay with electrochemical detection of free gamma-aminobutyric acid in cerebrospinal fluid. Clin Chem 1993;39:247-250.
10. Berthier M, Bonneau D, Desbordes JM, et al: Possible involvement of a gamma-hydroxybutyric acid receptor in startle disease. Acta Paediatr 1994;83:678-680.
11. Jakobs C, Jaeken J, Gibson KM: Inherited disorders of GABA metabolism. J Inherit Metab Dis 1993;16:704-715.
12. Jaeken J, Casaer P, de Cock P, et al: Gamma-aminobutyric acid-transaminase deficiency: A newly recognized inborn error of neurotransmitter metabolism. Neuropediatrics 1984;15:165-169.
13. Dubowitz LM, Bouza H, Hird MF, Jaeken J: Low cerebrospinal fluid concentration of free gamma-aminobutyric acid in startle disease. Lancet 1992;1340:80-81.
14. Shiang R, Ryan SG, Zhu YZ, et al: Mutations in the alpha 1 subunit of the inhibitory glycine receptor cause the dominant neurologic disorder, hyperekplexia. Nat Genet 1993;5:351-358.
15. Hoffmann GF, Surtees RA, Wevers RA: Cerebrospinal fluid investigations for neurometabolic disorders. Neuropediatrics 1998;29: 59-71.
16. Ben-Menachem E, Hamberger A, Mumford J: Effect of long-term vigabatrin therapy on GABA and other amino acid concentrations in the central nervous system - A case study. Epilepsy Res 1993;16:241-243.
17. Item CB, Stöckler-Ipsiroglu S, Stromberger C, et al: Arginine:glycine amidinotransferase deficiency: The third inborn error of creatine metabolism in humans. Am J Hum Genet 2001;69:1127-1133.
18. Stöckler S, Isbrandt D, Hanefeld F, et al: Guanidinoacetate methyltransferase deficiency: The first inborn error of creatine metabolism in man. Am J Hum Genet 1996;58:914-922.
19. Salomons GS, van Dooren SJ, Verhoeven NM, et al: X-linked creatine-transporter gene (SLC6A8) defect: A new creatine-deficiency syndrome. Am J Hum Genet 2001;68:1497-1500.
20. Stöckler S, Marescau B, De Deyn PP, et al: Guanidino compounds in guanidinoacetate methyltransferase deficiency, a new inborn error of creatine synthesis. Metabolism 1997;46:1189-1193.
21. Struys EA, Jansen EE, ten Brink HJ, et al: An accurate stable isotope dilution gas chromatographic-mass spectrometric approach to the diagnosis of guanidinoacetate methyltransferase deficiency. J Pharm Biomed Anal 1998;18:659-665.
22. Hyland K, Arnold LA: Value of lumbar puncture in the diagnosis of genetic metabolic encephalopathies. J Child Neurol 1999; 14(Suppl 1):S9-S15.
23. Blau N, Thony B, Cotton RG, Hyland K: Disorders of tetrahydrobiopterin and related biogenic amines, in Scriver CR, Beaudet AL, Sly WS, Valle D (eds): The Metabolic and Molecular Bases of Inherited Disease. New York, McGraw-Hill, 2001, 1725-1776.
24. Bonafe L, Thony B, Penzien JM, et al: Mutations in the sepiapterin reductase gene cause a novel tetrahydrobiopterin-dependent monoamine-neurotransmitter deficiency without hyperphenylalaninemia. Am J Hum Genet 2001;69:269-277.
25. Blau N, Bonafe L, Thony B: Tetrahydrobiopterin deficiencies without hyperphenylalaninemia: Diagnosis and genetics of doparesponsive dystonia and sepiapterin reductase deficiency. Mol Genet Melab 2001;74:172-185.
26. Ichinose H, Ohye T, Takahashi E, et al: Hereditary progressive dystonia with marked diurnal fluctuation caused by mutations in the GTP cyclohydrolase I gene. Nat Genet 1994;18:236-242.
27. Furukawa Y, Kish SJ, Bebin EM, et al: Dystonia with motor delay in compound heterozygotes for GTP-cyclohydrolase I gene mutations. Ann Neurol 1998;144:10-16.
28. Segawa M, Hosaka A, Miyagawa F, et al: Hereditary progressive dystonia with marked diurnal fluctuation., in Eldredge R, Fahn S (eds): Advances in Neurology. New York, Raven Press, 1976, 215-220.
29. Nygaard TG, Snow BJ, Fahn S, Calne DB: Dopa-responsive dystonia: Clinical characteristics and definitions, in Segawa M (ed): Hereditary Progressive Dystonia with Marked Diurnal Fluctuation. Lancaster, UK, Parthenon, 1993, 3-13.
30. Fink JK, Filling-Katz MR, Barton NW, et at: Treatable dystonia presenting as spastic cerebral palsy. Pediatrics 1988;82:137-138.
31. Nygaard TG: Dopa-responsive dystonia. Delineation of the clinical syndrome and clues to pathogenesis. Adv Neurol 1993;60: 577-585.
32. Brautigam C, Steenbergen-Spanjers GC, Hoffmann GF, et al: Biochemical and molecular genetic characteristics of the severe form of tyrosine hydroxylase deficiency. Clin Chem 1999;45: 2073-2078.
33. Swaans RJ, Rondot P, Renier WO, et al: Four novel mutations in the tyrosine hydroxylase gene in patients with infantile parkinsonism. Ann Hum Genet 2000;64:25-31.
34. Ludecke B, Knappskog PM, Clayton PT, etal: Recessively inherited L-dopa-responsive parkinsonism in infancy caused by a point mutation (L205P) in the tyrosine hydroxylase gene. Hum Mol Genet 1996;15:1023-1028.
35. Furukawa Y, Graf WD, Wong H, et al: Dopa-responsive dystonia simulating spastic paraplegia due to tyrosine hydroxylase (TH) gene mutations. Neurology 2001;56:260-263.
36. Knappskog PM, Flatmark T, Mallet J, et al: Recessively inherited L-dopa-responsive dystonia caused by a point mutation (Q381K) in the tyrosine hydroxylase gene. Hum Mol Genet 1995;14: 1209-1212.
37. De Lonlay P, Nassogne MC, van Gennip A.H, et al: Tyrosine hydroxylase deficiency unresponsive to L-dopa treatment with unusual clinical and biochemical presentation. J Inherit Metab Dis 2000; 23:819-825.
38. Hyland K, Surtees RA, Rodeck C, Clayton PT: Aromatic L-amino acid decarboxylase deficiency: Clinical features, diagnosis, and treatment of a new inborn error of neurotransmitter amine synthesis. Neurology 1992;42:1980-1988.
39. Swoboda K, Hyland K, Goldstein D, et al: Clinical and therapeutic observations in aromatic L-amino acid decarboxylase deficiency. Neurology 1999;53:1205-1211.
40. Fiamura A, Brautigam C, Hyland K, et al: Aromatic L-amino acid decarboxylase deficiency with hyperdopaminuria. Clinical and laboratory findings in response to different therapies. Neuropediatrics 2002;33:203-208.
41. Abeling NG, van Gennip AH, Barth PG, et al: Aromatic L-amino acid decarboxylase deficiency: A new case with a mild clinical presentation and unexpected laboratory findings. J Inherit Metab Dis 1998;21:240-242.
42. Burlina AB, Burlina AP, Hyland K, et at: Autistic syndrome and aromatic L-amino acid decarboxylase (AADC) deficiency, abstract. J Inherit Metab Dis 2001;24(Suppl 1):34.
43. Robertson D, Haile V, Perry SE, et al: Dopamine beta-hydroxylase deficiency. A genetic disorder of cardiovascular regulation. Hypertension 1991;18:1-8.
44. Abeling NG, van Gennip AH, van Cruchten AG, et al: Monoamine oxidase A deficiency: Biogenic amine metabolites in random urine samples. J Neurol Transm Suppl 1998;52:9-15.
45. de la Chapelle A, Sankila EM, Lindlof M, et al: Norrie disease caused by a gene deletion allowing carrier detection and prenatal diagnosis. Clin Genet 1985;28:317-320.
46. Brunner HG, Nelen M, Breakefield XO, et al: Abnormal behavior associated with a point mutation in the structural gene for monoamine oxidase A. Science 1993;262:578-580.
47. Collins FA, Murphy DL, Reiss AL, et al: Clinical, biochemical, and neuropsychiatric evaluation of a patient with a contiguous gene syndrome due to a microdeletion Xp11.3 including the Norrie disease locus and monoamine oxidase (MAOA and MAOB) genes. Am J Med Genet 1992;42:127-134.
48. Lenders JW, Eisenhofer G, Abeling NG, et al: Specific genetic deficiencies of the A and B isoenzymes of monoamine oxidase are characterized by distinct neurochemical and clinical phenotypes. J Clin Invest 1996;197:1010-1019.
49. Gross PT, Berlow S, Schuett VE, Fariello RG: EEG in phenylketonuria. Attempt to establish clinical importance of EEG changes. Arch Neurol 1981;138:122-126.
50. Koslacz-Folga A, Jackowska K, Czochanska J, et al: Convulsions in phenylketonuria and the pattern of the bioelectric activity of the brain. Neurol Neurochir Pol 1977;11:407-413.
51. Knowles RG, Moncada S: Nitric oxide synthases in mammals. Biochem J 1994;298:249-258.
52. Brand MP, Briddon A, Land JM, et al: Impairment of the nitric oxide/cyclic GMP pathway in cerebellar slices prepared from the hph-1 mouse. Brain Res 1996;735:169-172.
53. Heales SJ, Canevari L, Brand MP, et al: Cerebrospinal fluid nitrite plus nitrate correlates with tetrahydrobiopterin concentration. J Inherit Metab Dis 1999;22:221-223.
54. Kiss JP, Vizi ES: Nitric oxide: A novel link between synaptic and nonsynaptic transmission. Trends Neurosci 2001;24:211-215.
55. Heneka MT, Feinstein DL: Expression and function of inducible nitric oxide synthase in neurons. J Neuroimmunol 2001;114:8-18.
56. Riedel W. Role of nitric oxide in the control of the hypothalamic-pituitary-adrenocortical axis. Z Rheumatol 2000;59(Suppl 2):36-42.
57. Prast H, Philippu A: Nitric oxide as modulator of neuronal function. Prog Neurobiol 2001;64:51-68.
58. Torres OA, Miller VS, Buist NM, Hyland K: Folinic acid-responsive neonatal seizures. J Child Neurol 1999;14:529-532.
59. Hyland K, Buist NR, Powell BR, et al: Folinic acid responsive seizures: A new syndrome? J Inherit Metab Dis 1995;18:177-181.
60. Hyland K, Peterschmitt MJ, Soull JS, et al: Confusing CSF neurochemical picture suggesting 6-pyruvoyltetrahydropterin synthase deficiency in neonates with probable hypoxic-ischemic encephalopathy. J Inherit Metab Dis 1999;22:18.
61. Huber C, Batchelor JR, Fuchs D, et al: Immune response-associated production of neopterin. Release from macrophages primarily under control of interferon-gamma. J Exp Med 1984;160: 310-316.